论文部分内容阅读
随着分子靶向药物的研发,放射核素碘-131(131Ⅰ)分子靶向治疗已成为原发性肝癌(HCC)治疗的研究热点。通过复习国内、外相关文献,总结131Ⅰ标记不同的耦联物靶向治疗HCC的临床研究与应用,表明131Ⅰ分子靶向治疗HCC具有较好的安全性和有效性。放射性核素131Ⅰ标记的耦联物也有了新的进展,如131Ⅰ可标记23-羟基白桦酸、单克隆抗体以及其他分子靶向治疗药物。但如何提高疗效及分子靶向性等问题仍有待解决。
With the development of molecular targeted drugs, the radionuclide iodine-131 (131Ⅰ) molecular targeted therapy has become a hot research topic in the treatment of primary liver cancer (HCC). Through the review of domestic and foreign literature, summarize the clinical research and application of 131I labeled different conjugates targeted therapy of HCC, indicating that 131I molecular targeted therapy of HCC has good safety and effectiveness. New developments have also been made in the conjugation of the 131 I labeled radionuclides, such as 131 I labeling of 23-hydroxy betulinic acid, monoclonal antibodies and other molecular targeted therapies. However, how to improve curative effect and molecular targeting remains to be solved.